# Evidence-Based Guidelines for Medical Cannabis: Utah Department of Health > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/2026-cannabis-clinical-guidelines-utah-medical-cannabis/ > **Published:** 2026-04-04T23:12:09-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:30:29-04:00 > **Clinical Summary:** Explore the 2026 cannabis clinical guidelines shaping medical cannabis use in Utah with evidence-based standards and regulatory insights. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Clinical Guidelines[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/)Evidence-Based MedicineRegulatory FrameworkUtah Why This Matters State-level evidence-based guidelines represent a critical step toward standardizing [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice and reducing the current variability in clinical recommendations. Utah’s approach could influence how other states structure their [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs and clinical oversight. Clinical Summary Utah has developed evidence-based guidelines for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), presumably drawing from available [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) to inform dosing, indications, and safety protocols. While the specific content of these guidelines isn’t detailed in the summary, state-sponsored clinical guidance represents an institutional effort to move beyond anecdotal recommendations toward more rigorous clinical standards. This follows Utah’s conservative but methodical approach to medical cannabis implementation since their program’s inception. Dr. Caplan’s Take “I’m encouraged to see states investing in evidence-based frameworks, though the devil is always in the details—how rigorous is the evidence review, and do the recommendations reflect clinical reality or regulatory caution? Utah’s guidelines could become a model if they strike the right balance between available evidence and practical clinical utility.” Clinical Perspective 🧠 Clinicians should review these guidelines to understand Utah’s interpretation of current evidence and compare it with their own clinical experience and other authoritative sources. While state guidelines provide important regulatory context, they should be considered alongside peer-reviewed literature and clinical judgment rather than as definitive clinical protocols. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Evidence%20based%20guidelines%20%7C%20Center%20for%20Medical%20Cannabis%20%7C%20Utah%20Department%20of%20Hea...%20%40drcaplan&url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines-2/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines-2/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Evidence%20based%20guidelines%20%7C%20Center%20for%20Medical%20Cannabis%20%7C%20Utah%20Department%20of%20Hea...%20--%20via%20%40drcaplan.bsky.social%20https%3A//medicalcannabis.utah.gov/evidence-based-guidelines-2/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://medicalcannabis.utah.gov/evidence-based-guidelines-2/](https://medicalcannabis.utah.gov/evidence-based-guidelines-2/) Table of Contents - [FAQ](#FAQ)[What type of clinical development does this article represent?](#What_type_of_clinical_development_does_this_article_represent) - [What areas of cannabis medicine does this update cover?](#What_areas_of_cannabis_medicine_does_this_update_cover) - [Why is this classified as “Notable Clinical Interest”?](#Why_is_this_classified_as_8220Notable_Clinical_Interest8221) - [What should healthcare providers do with this information?](#What_should_healthcare_providers_do_with_this_information) - [How does this relate to evidence-based cannabis medicine?](#How_does_this_relate_to_evidence-based_cannabis_medicine) - [Related](#Related) ## FAQ #### What type of clinical development does this article represent? This article represents a notable clinical interest development with emerging findings or policy developments in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). It’s classified as CED Clinical Relevance #76, indicating it contains information worth monitoring closely by healthcare professionals. #### What areas of cannabis medicine does this update cover? The update covers clinical guidelines, [state policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/) changes, evidence-based medicine developments, and regulatory framework modifications. These represent the key pillars of cannabis medical practice and legal implementation. #### Why is this classified as “Notable Clinical Interest”? The classification indicates this contains emerging findings or policy developments that healthcare providers should monitor closely. It suggests the information may impact clinical practice or patient care in the cannabis medicine field. #### What should healthcare providers do with this information? Healthcare providers should review these developments as they may affect clinical practice guidelines and patient treatment protocols. The “Notable Clinical Interest” designation suggests providers should stay informed about these evolving standards and regulations. #### How does this relate to evidence-based cannabis medicine? This update contributes to the growing body of evidence-based medicine in cannabis treatment by providing clinical guidelines and regulatory framework updates. It helps establish standardized approaches to cannabis medicine within appropriate legal and clinical parameters. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Medical Cannabis Significantly Reduced Use of Opioids and Other Rx Drugs](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) Explore research showing how medical cannabis use can reduce reliance on opioids and prescription medications. [Read More](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) [Q&A: What Does Science Say About Plants as Medicine?](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) A detailed discussion on the scientific evidence supporting the use of plants, including cannabis, in medical treatment. [Learn More](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) [Today We Can Start Medical Research in the USA on Cannabis](https://cedclinic.com/starting-federally-backed-cannabis-clinical-trials-usa/) Insights into the evolving landscape of cannabis [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) in the United States and its future implications. [Explore Now](https://cedclinic.com/starting-federally-backed-cannabis-clinical-trials-usa/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).